Ociperlimab represents a very encouraging development in addressing self-immune disorders. This experimental antibody therapy targets neonatal Fc receptor γ , the protein involved in activating https://ociperlimabinvitrostudy381332.activoblog.com/54336179/ociperlimab-this-promising-strategy-in-self-immune-illness